802 articles
New study of 96,000 people shows brief bursts of intense activity dramatically reduce risks of heart disease, dementia, and diabetes.
Comprehensive analysis reveals whole dietary patterns, not individual supplements, show strongest connection to reduced depression in adolescents.
UK biotech secures major funding for antibody therapy targeting protein buildup that damages hearts in amyloidosis patients.
Rubedo's RLS-1496 demonstrates early clinical signals in removing senescent cells through GPX4 modulation in human skin tissue.
Topical therapy RLS-1496 met primary endpoints in Phase 1 trial with no serious adverse events in psoriasis patients.
Maze Therapeutics' MZE829 reduced kidney damage markers by over 35% in patients with APOL1-mediated kidney disease in Phase 2 trials.
New study of 96,000 people shows brief bursts of intense activity dramatically reduce risks of heart disease, dementia, and diabetes.
Stanford-Buck coalition develops intrinsic capacity score to quantify aging and test interventions through YMCA partnerships.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.
WHO-commissioned reviews find Ozempic and similar drugs deliver up to 16% weight loss, but long-term safety data remains limited.
Scientists discover nerve fibers create a self-sustaining loop that accelerates pancreatic cancer development before tumors even form.
Analysis of 123,940 patients reveals most reported statin side effects occur equally in placebo groups, challenging widespread medication fears.
